Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders

Jones HW, McDowell J, Acosta A, et al. The importance of the follicular phase to success and failure in in vitro fertilisation. Fertil Steril 1983;40:317–21. Jenkins JM, Davies DW, Devonport H, et al. Comparison of ‘poor’ responders with ‘good’ responders using a standard buserelin/human menopausal gonadotropin regime for in vitro fertilization. Hum Reprod 1991;6:918–21. Land, 1996, High-dose human menopausal gonadotropin stimulation in poor responders does not improve the in vitro fertilization outcome, Fertil. Steril., 65, 961, 10.1016/S0015-0282(16)58269-7 Serafini P, Stone B, Kerin J, et al. An alternate approach to controlled ovarian hyperstimulation in ‘poor responders’: pretreatment with a gonadotropin-releasing hormone analog. Fertil Steril 1988;49:90–5. Ben-Rafael, 1991, Ovarian hyporesponsiveness in combined gonadotropin-releasing hormone agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levels, Fertil. Steril., 55, 272, 10.1016/S0015-0282(16)54114-4 Casper, 1982, The effects of luteinizing hormone releasing factor and its agonist on cultured human granulosa cells, Fertil. Steril., 37, 406, 10.1016/S0015-0282(16)46105-4 Sheehan, 1982, Induction of luteolysis by luteinizing hormone releasing factor (LRF) agonist: sensitivity, reproducibility, and reversibility, Fertil. Steril., 37, 209, 10.1016/S0015-0282(16)46041-3 Klingmóller, 1993, Hormonal response to the new GnRH antagonist Cetrorelix, Acta Endocrinol., 128, 15, 10.1530/acta.0.1280015 Felberbaum RE, Reissmann T, Kópker W, et al. Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin-releasing hormone (GnRH) antagonist Cetrorelix at different dosages. J Asst Reprod Genet 1996;13:216–22. Olivennes F, Fancin R, Bouchard P, et al. The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer programme. Fertil Steril 1994;62:468–76. Olivennes F, Fanchin R, Bouchard P, et al. Scheduled administration of a gonadotropin-releasing hormone antagonist (Cetrorelix) on day 8 of in vitro fertilization cycles: a pilot study. Hum Reprod 1995;10:1382–86. Albano C, Smitz J, Camus M, et al. Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotropin and gonadotropin-releasing hormone antagonist (Cetrorelix). Hum Reprod 1996;11:2114–18. Albano C, Smitz J, Camus M, et al. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997;67:917–22. Felberbaum RE. Cetrorelix in controlled ovarian stimulation for ART: results of phase III, multiple dose treatment. In: Proceedings of the 5th International Symposium on GnRH Analogues in Cancer and Human Reproduction (Abstract 28). Gyn Endocrinol 1999;13(Suppl 1). Toner, 1991, Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age, Fertil. Steril., 55, 784, 10.1016/S0015-0282(16)54249-6 Navot, 1989, Prognostic assessment of female fecundity, Lancet, 2, 645 Winslow KL, Toner JP, Bryski RG, et al. The gonadotropin-releasing hormone agonist stimulation test — a sensitive predictor of performance in the flare-up in vitro fertilisation cycle. Fertil Steril 1991;56:711–17. Roest J, van Heusden AM, Mous H, et al. The ovarian response as a predictor for successful in vitro fertilization treatment after the age of 40 years. Fertil Steril 1996;66:969–73. Van Steirteghem AC, Nagy Z, Joris H, et al. High fertilization and implantation rate after intracytoplasmic sperm injection. Hum Reprod 1993;8:1061–66. Al-Hasani S, Kópker W, Baschat AA, et al. Mini swim-up: a new technique of sperm preparation for ICSI. J Assist Reprod Genet 1995;12:428–33. Veeck L. Preembryo grading. In: Brown CL, Vaughn VM, Lumpkin K, editors. Atlas of the human oocyte and early concepts. Baltimore (USA): Williams & Wilkins, 1991. p. 121–31. Steer CV, Mills CL, Tan SL, et al. The cumulative embryo score: a predictive embryo scoring technique to select the optimal number of embryos to transfer in an IVF-ET programme. Hum Reprod 1992;7:117–19. Feldberg D, Farhi J, Ashkenazi J, et al. Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels. Fertil Steril 1994;62:343–46. Barri PN, Martinez F, Coroleu B, et al. Managing nonresponders. In: Kempers RD, Cohen J, Haney AF, Younger JB, editors. Proceedings of the XVI World Congress on Fertility and Sterility. 1998 Oct; San Francisco. Amsterdam: Elsevier, p. 127–37. Lashen, 1999, Poor responders to ovulation induction: is proceeding to in vitro fertilization worthwhile?, Hum. Reprod., 14, 964, 10.1093/humrep/14.4.964 Dor J, Seidman DS, Amudai E, et al. Adjuvant GH therapy in poor responders to IVF: a prospective randomized placebo controlled double blind study. Hum Reprod 1995;10:40–3. Jinno, 1996, A novel method of ovarian stimulation for in vitro fertilization: bromocriptine rebound method, Fertil. Steril., 66, 271, 10.1016/S0015-0282(16)58452-0 Karande, 1990, High-dose FSH stimulation at the onset of the menstrual cycle does not suppress the IVF outcome of low-responder patients, Fertil. Steril., 53, 486, 10.1016/S0015-0282(16)53345-7 Meldrum DR, Wisot A, Hamilton F, et al. Routine pituitary suppression with leuprolide before ovarian stimulation for, oocyte retrieval. Fertil Steril 1989;51:455–59. Fujii S, Sagara M, Kudo H, et al. A prospective randomized comparison between long and discontinuous-long protocols of gonadotropin-releasing hormone agonist for in vitro fertilization. Fertil Steril 1997;67:1166–68. Ben-Rafael Z, Menashe Y, Mimon R, et al. Limitations in the use of combined gonadotropin-releasing hormone analog and human menopausal gonadotropin for in vitro fertilisation. In: Mashiach S, Ben-Rafael Z, Laufer N, Schenker JG, editors. Advances in assisted reproductive technologies. New York (NY, USA): Plenum Press, 1990. p. 17–30. Van Hooff MHA, Alberda AT, Huisman GJ, et al. Doubling the human menopausal gonadotropin dose in the course of an in vitro fertilization treatment cycle in low responders: a randomized study. Hum Reprod 1993;8:369–73. Regan, 1990, Hypersecretion of luteinising hormone, infertility, and miscarriage, Lancet, 2, 1141, 10.1016/0140-6736(90)92765-A Olivennes F, Fanchin R, Bouchard P, et al. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist. Fertil Steril 1996;66:151–53. Felberbaum RE, Reissmann T, Kópker W, et al. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility. Eur J Obstet Gyn Reprod Biol 1995;61:151–55. Felberbaum RE, Diedrich K. Ovarian stimulation in ART: use of GnRH antagonists. In: Proceedings of the XVI World Congress on Fertility and Sterility, 1998 Oct 4–9; San Francisco. Fertility and reproductive medicine. Amsterdam: Elsevier, 1998. p. 113–25. Moreno C, Ruiz A, Simon C, et al. Intracytoplasmic sperm injection as a routine indication in low responder patients. Hum Reprod 1998;13:2126–29. Ludwig M, Al-Hasani S, Kupker W, et al. A new indication for an intracytoplasmic sperm injection procedure outside the cases of severe male factor infertility. Eur J Obstet Gyn Reprod Biol 1997;75:207–10.